{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:22:20Z","timestamp":1772252540364,"version":"3.50.1"},"reference-count":137,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>A large number of novel treatments for myeloma have been developed and approved; however, alkylating drugs continue to be part of standard regimens. Additionally, novel alkylators are currently being developed. We performed a non-systematized literary search for relevant papers and communications at large conferences, as well as exploiting the authors\u2019 knowledge of the field, to review the history, current use and novel concepts around the traditional alkylators cyclophosphamide, bendamustine and melphalan and current data on the newly developed pro-drug melflufen. Even in the era of targeted treatment and personalized medicine, alkylating drugs continue to be part of the standard-of-care in myeloma, and new alkylators are coming to the market.<\/jats:p>","DOI":"10.3390\/cancers13102465","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T23:34:46Z","timestamp":1621380886000},"page":"2465","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Current and Novel Alkylators in Multiple Myeloma"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-0569","authenticated-orcid":false,"given":"Fredrik","family":"Schjesvold","sequence":"first","affiliation":[{"name":"Oslo Myeloma Center, Oslo University Hospital, 0450 Oslo, Norway"},{"name":"K.G. Jebsen Centre for B-Cell Malignancies, University of Oslo, 4950 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"Institut Josep Carreras and Institut Catal\u00e0 d\u2019Oncologia, Hospital Germans Trias I Pujol, 08916 Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1001\/jama.1919.26110010018009f","article-title":"R\u00f4le of the Blood and the bone marrow in certain forms of gas poisoning: I. peripheral blood changes and their significance","volume":"72","author":"Krumbhaar","year":"1919","journal-title":"J. Am. Med. Assoc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/0002-9610(63)90232-0","article-title":"The initial clinical trial of nitrogen mustard","volume":"105","author":"Gilman","year":"1963","journal-title":"Am. J. Surg."},{"key":"ref_4","first-page":"6","article-title":"Cytotoxic \u03b1 amino acids and peptides","volume":"31","author":"Bergel","year":"1953","journal-title":"Br. Emp. Cancer Campain"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1749-6632.1958.tb42675.x","article-title":"Clinical experiences with sarcolysin in neoplastic diseases","volume":"68","author":"Blokhin","year":"1958","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","article-title":"Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens","volume":"208","author":"Alexanian","year":"1969","journal-title":"JAMA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(83)90739-0","article-title":"High-dose intravenous melphalan for plasma-cell leukaemia and myeloma","volume":"2","author":"McElwain","year":"1983","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","article-title":"A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome","volume":"335","author":"Attal","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood.V69.4.1262.1262","article-title":"Bone marrow transplantation in multiple myeloma: Report from the European Cooperative Group for Bone Marrow Transplantation","volume":"69","author":"Gahrton","year":"1987","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2141.2007.06639.x","article-title":"Incorporating bortezomib into upfront treatment for multiple myeloma: Early results of total therapy 3","volume":"138","author":"Barlogie","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ajh.24954","article-title":"Efficacy of VDT PACE-like regimens in treatment of relapsed\/refractory multiple myeloma","volume":"93","author":"Lakshman","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","article-title":"The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications","volume":"101","author":"Mitsiades","year":"2003","journal-title":"Blood"},{"key":"ref_15","first-page":"1136","article-title":"The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents","volume":"9","author":"Ma","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"Schlag","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3324\/haematol.12106","article-title":"Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: Updated time-to-events results and prognostic factors for time to progression","volume":"93","author":"Mateos","year":"2008","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1200\/JCO.2012.41.6180","article-title":"Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma","volume":"31","author":"Schlag","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: Results of a randomized trial from the Turkish Myeloma Study Group","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: Meta-analysis of 1685 individual patient data from 6 randomized clinical trials","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/blood-2015-08-662627","article-title":"Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma","volume":"127","author":"Magarotto","year":"2016","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","article-title":"Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"133","author":"Facon","year":"2019","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous Therapy Versus Fixed Duration of Therapy in Patients with Newly Diagnosed Multiple Myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","article-title":"Comparison of 200 mg\/m2 melphalan and 8 Gy total body irradiation plus 140 mg\/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger)","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early Versus Late Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the IFM 2009 Trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.bbmt.2020.08.018","article-title":"The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study","volume":"26","author":"Cowan","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/bjh.16764","article-title":"The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: Is it time for a paradigm shift?","volume":"191","author":"Kazandjian","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1182\/blood-2018-99-112899","article-title":"Double Vs Single Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: Long-Term Follow-up (10-Years) Analysis of Randomized Phase 3 Studies","volume":"132","author":"Cavo","year":"2018","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): A multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8506","DOI":"10.1200\/JCO.2020.38.15_suppl.8506","article-title":"Long-term follow-up of BMT CTN 0702 (STaMINA) of postautologous hematopoietic cell transplantation (autoHCT) strategies in the upfront treatment of multiple myeloma (MM)","volume":"38","author":"Hari","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): A randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Goldschmidt, H., Baertsch, M.A., Schlenzka, J., Becker, N., Habermehl, C., Hielscher, T., Raab, M.S., Hillengass, J., Sauer, S., and Muller-Tidow, C. (2020). Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide\/dexamethasone for relapsed multiple myeloma: The randomized GMMG phase III trial ReLApsE. Leukemia.","DOI":"10.1038\/s41375-020-0948-0"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.leukres.2018.07.016","article-title":"Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma","volume":"74","author":"Radivoyevitch","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-139014","article-title":"High-Dose Melphalan Significantly Increases Mutational Burden in Multiple Myeloma Cells at Relapse: Results from a Randomized Study in Multiple Myeloma","volume":"136","author":"Samur","year":"2020","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00277-011-1401-2","article-title":"Cyclophosphamide-containing regimen (TCD) is superior to melphalan-containing regimen (MPT) in elderly multiple myeloma patients with renal impairment","volume":"91","author":"Song","year":"2012","journal-title":"Ann. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/cncr.24221","article-title":"The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and \u03b1(2)\u03b2 interferon versus VBMCP: Results of a phase III Eastern Cooperative Oncology Group Study E5A93","volume":"115","author":"Kyle","year":"2009","journal-title":"Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.clml.2019.05.001","article-title":"Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia","volume":"19","author":"Tabchi","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2016.176","article-title":"A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)","volume":"31","author":"Hajek","year":"2017","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1038\/leu.2015.274","article-title":"Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma","volume":"29","author":"Cavo","year":"2015","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: Results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3747\/co.27.5385","article-title":"Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma","volume":"27","author":"Figueiredo","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/bmt.2014.288","article-title":"CyBorD induction therapy in clinical practice","volume":"50","author":"Areethamsirikul","year":"2015","journal-title":"Bone Marrow Transpl."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/bjh.14920","article-title":"Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial","volume":"179","author":"Einsele","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"ref_60","unstructured":"Mina, R., Bonello, F., Petrucci, M.T., Liberati, A.M., Conticello, C., Ballanti, S., Musto, P., Olivieri, A., Benevolo, G., and Capra, A. (2020). Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: A pooled analysis of two studies. Haematologica."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood-2020-140934","article-title":"Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg\/m2 and Dexamethasone Plus\/Minus Cyclophosphamide in Relapsed and\/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)","volume":"136","author":"Mateos","year":"2020","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1097\/HS9.0000000000000350","article-title":"Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma","volume":"4","author":"Swan","year":"2020","journal-title":"Hemasphere"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-2141.2010.08250.x","article-title":"The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed\/refractory myeloma patients; a phase I\/II study","volume":"150","author":"Schey","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bjh.13100","article-title":"Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma","volume":"168","author":"Reece","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2016-07-729236","article-title":"Phase 1\/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"34009","DOI":"10.18632\/oncotarget.26131","article-title":"Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients","volume":"9","author":"Franssen","year":"2018","journal-title":"Oncotarget"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1158\/0008-5472.CAN-11-3912","article-title":"Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective","volume":"72","author":"Le","year":"2012","journal-title":"Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/blood-2013-03-488676","article-title":"Pomalidomide, cyclophosphamide, and prednisone for relapsed\/refractory multiple myeloma: A multicenter phase 1\/2 open-label study","volume":"122","author":"Larocca","year":"2013","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Lee, H.S., Kim, K., Kim, S.J., Lee, J.J., Kim, I., Kim, J.S., Eom, H.S., Yoon, D.H., Suh, C., and Shin, H.J. (2020). Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study). Am. J. Hematol.","DOI":"10.1002\/ajh.25726"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-019-03649-3","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for relapsed\/refractory multiple myeloma patients in a real-life setting: A single-center retrospective study","volume":"98","author":"Trudel","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): A randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood-2018-07-863829","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma","volume":"132","author":"Garderet","year":"2018","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-019-0206-8","article-title":"Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: Results of the phase II PERSPECTIVE Multiple Myeloma trial","volume":"9","author":"Weisel","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1080\/10428194.2020.1805111","article-title":"A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"61","author":"Parekh","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-135874","article-title":"Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"136","author":"Dimopoulos","year":"2020","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-141087","article-title":"A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma","volume":"136","author":"Sebag","year":"2020","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Hiraoka, N., Kikuchi, J., Yamauchi, T., Koyama, D., Wada, T., Uesawa, M., Akutsu, M., Mori, S., Nakamura, Y., and Ueda, T. (2014). Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090675"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","article-title":"Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines","volume":"7","author":"Strumberg","year":"1996","journal-title":"Anticancer Drugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","article-title":"Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents","volume":"14","author":"Leoni","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Barcellini, W., Zaninoni, A., Giannotta, J.A., and Fattizzo, B. (2020). New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1. J. Clin. Med., 9.","DOI":"10.3390\/jcm9123859"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus treatment recommendations from the tenth International Workshop for Waldenstrom Macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/17474086.2019.1652589","article-title":"Novel therapeutics in hairy cell leukemia","volume":"12","author":"Sarvaria","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.24826","article-title":"Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment","volume":"92","author":"Hallek","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"103038","DOI":"10.1016\/j.critrevonc.2020.103038","article-title":"Mantle cell lymphoma","volume":"153","author":"Cortelazzo","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/hon.2781","article-title":"Precision medicine in follicular lymphoma: Focus on predictive biomarkers","volume":"38","author":"Sorigue","year":"2020","journal-title":"Hematol. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11864-019-0687-5","article-title":"Marginal Zone Lymphoma: State-of-the-Art Treatment","volume":"20","author":"Sindel","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","article-title":"Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone\u2014A randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)","volume":"132","author":"Ponisch","year":"2006","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2141.2008.07076.x","article-title":"Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: Results of a Phase I clinical trial","volume":"143","author":"Ponisch","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2141.2011.08754.x","article-title":"Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease","volume":"155","author":"Ramasamy","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/blood-2011-12-395715","article-title":"Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: Results of phase 1\/2 open-label, dose escalation study","volume":"119","author":"Lentzsch","year":"2012","journal-title":"Blood"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bjh.12129","article-title":"Phase I\/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma","volume":"160","author":"Berenson","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjh.12361","article-title":"Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: Final results of a phase 1 clinical trial OSHO-#077","volume":"162","author":"Ponisch","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00432-012-1339-3","article-title":"Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma","volume":"139","author":"Ponisch","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood-2013-08-521468","article-title":"Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma","volume":"123","author":"Ludwig","year":"2014","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.3324\/haematol.2014.110890","article-title":"Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: The Intergroupe Francophone du Myelome 2009-01 trial","volume":"100","author":"Rodon","year":"2015","journal-title":"Haematologica"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/bjh.13435","article-title":"Bendamustine, thalidomide and dexamethasone combination therapy for relapsed\/refractory myeloma patients: Results of the MUKone randomized dose selection trial","volume":"170","author":"Schey","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ajh.24181","article-title":"Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma","volume":"90","author":"Kumar","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1080\/10428194.2016.1205741","article-title":"Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed\/refractory multiple myeloma confirms very promising results in a phase I\/II study","volume":"58","author":"Pozzi","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/bjh.14481","article-title":"Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma-a phase II trial","volume":"176","author":"Mey","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1007\/s00432-017-2504-5","article-title":"Lenalidomide in combination with bendamustine and prednisolone in relapsed\/refractory multiple myeloma: Results of a phase 2 clinical trial (OSHO-#077)","volume":"143","author":"Beck","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41408-018-0104-5","article-title":"Bendamustine, pomalidomide, and dexamethasone for relapsed and\/or refractory multiple myeloma","volume":"8","author":"Sivaraj","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.1200\/JCO.2018.36.15_suppl.8019","article-title":"Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial","volume":"36","author":"Gramatzki","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/bjh.15645","article-title":"Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib","volume":"185","author":"Mian","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-019-0219-3","article-title":"Phase I\/II trial of bendamustine, ixazomib, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"9","author":"Dhakal","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): A randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2014-02-556308","article-title":"A phase 2 single-center study of carfilzomib 56 mg\/m2 with or without low-dose dexamethasone in relapsed multiple myeloma","volume":"124","author":"Lendvai","year":"2014","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.3109\/10428194.2015.1106531","article-title":"Bendamustine and dexamethasone are an effective salvage regimen for patients with advanced multiple myeloma in a Home Care Unit program","volume":"57","author":"Gentilini","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.bbmt.2013.02.013","article-title":"A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma","volume":"19","author":"Mark","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41409-019-0587-0","article-title":"High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma","volume":"54","author":"Mark","year":"2019","journal-title":"Bone Marrow Transpl."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/bmt.2016.94","article-title":"A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy","volume":"51","author":"Martino","year":"2016","journal-title":"Bone Marrow Transpl."},{"key":"ref_117","first-page":"1096","article-title":"Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: Results of a prospective phase 2 Spanish\/PETHEMA trial","volume":"100","author":"Mateos","year":"2015","journal-title":"Haematologica"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/bjh.14536","article-title":"Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy","volume":"177","author":"Berdeja","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41408-020-0278-5","article-title":"Phase I\/II study of carfilzomib, bendamustine, and dexamethasone (CBD) in patients with newly diagnosed multiple myeloma","volume":"10","author":"Leng","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"66641","DOI":"10.18632\/oncotarget.18420","article-title":"Melflufen-a peptidase-potentiated alkylating agent in clinical trials","volume":"8","author":"Wickstrom","year":"2017","journal-title":"Oncotarget"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e395","DOI":"10.1016\/S2352-3026(20)30044-2","article-title":"Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): A multicentre, international, open-label, phase 1\u20132 study","volume":"7","author":"Richardson","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_122","first-page":"1883","article-title":"Clinical activity of melflufen in patients with triple-class refractory multiple myeloma and poor-risk features in an updated analysis of HORIZON (OP-106), a phase 2 study in patients with relapsed\/refractory multiple myeloma refractory to pomalidomide and\/or daratumumab","volume":"133","author":"Mateos","year":"2019","journal-title":"ASH Annu. Meet. Abstr."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Ocio, E.M., Efebera, Y.A., Granell, M., Hajek, R., Maisnar, V., Karlin, L., Mateos, M.V., Richardson, P.G., Oriol, A., and Norin, S. (2019, January 7\u201310). ANCHOR (OP-104): Updated efficacy and safety from a phase 1\/2 study of melflufen and dexamethasone plus bortezomib or daratumumab in patients with relapsed\/refractory multiple myeloma (RRMM) refractory to an IMiD or a proteasome inhibitor (PI). Proceedings of the 61st American Society of Hematology Annual Meeting, Orlando, FL, USA.","DOI":"10.1182\/blood-2019-124815"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1158\/1078-0432.CCR-12-3752","article-title":"In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells","volume":"19","author":"Chauhan","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00726-013-1648-0","article-title":"Positioning of aminopeptidase inhibitors in next generation cancer therapy","volume":"46","author":"Hitzerd","year":"2014","journal-title":"Amino Acids"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1158\/1535-7163.MCT-08-0735","article-title":"Aminopeptidase inhibition as a targeted treatment strategy in myeloma","volume":"8","author":"Moore","year":"2009","journal-title":"Mol. Cancer Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1349-7006.2010.01826.x","article-title":"Aminopeptidase N (CD13) as a target for cancer chemotherapy","volume":"102","author":"Wickstrom","year":"2011","journal-title":"Cancer Sci."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjh.14065","article-title":"A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells","volume":"174","author":"Ray","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Slipicevic, A., Munawar, U., Aschan, J., Lehmann, F., Miettinen, J., Huppunen, M.-E., Bargou, R.C., Nupponen, N.N., Rodriguez, P., and Richardson, P. (2020, January 22\u201324). Melflufen efficacy in multiple myeloma with TP53 aberrations. Proceedings of the American Association for Cancer Research (AACR) Annual Meeting, Virtual Annual Meeting II, Philadelphia, PA, USA.","DOI":"10.1158\/1538-7445.AM2020-1843"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/fon-2020-0024","article-title":"OCEAN: A randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma","volume":"16","author":"Schjesvold","year":"2020","journal-title":"Future Oncol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-135991","article-title":"ANCHOR (OP-104): Melflufen Plus Dexamethasone (dex) and Daratumumab (dara) or Bortezomib (BTZ) in Relapsed\/Refractory Multiple Myeloma (RRMM) Refractory to an IMiD and\/or a Proteasome Inhibitor (PI)-Updated Efficacy and Safety","volume":"136","author":"Ocio","year":"2020","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1200\/JCO.20.02259","article-title":"Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1096\/fba.2018-00075","article-title":"The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis","volume":"1","author":"Oliveira","year":"2019","journal-title":"FASEB BioAdv."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/10\/2465\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:03:40Z","timestamp":1760162620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/10\/2465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":137,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["cancers13102465"],"URL":"https:\/\/doi.org\/10.3390\/cancers13102465","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202103.0150.v1","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]}}}